Finally, a small non-randomized but matched-controlled pilot study compared three months of vagal breathing via HRV biofeedback and chemotherapy, to controls who received only chemotherapy and matched for tumor type and stage, chemotherapy line, and baseline CEA levels. The gene discussed is CEACAM5; the disease is neoplasm.